Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention

• Príomhchruthaitheoirí: Nicolas Lecrenier (Údar), Pierre Beukelaers (Údar), Romulo Colindres (Údar), Desmond Curran (Údar), Carine De Kesel (Údar), Jean-Philippe De Saegher (Údar), Arnaud M Didierlaurent (Údar), Edouard Y Ledent (Údar), Johann F Mols (Údar), Tomas Mrkvan (Údar), Marie Normand-Bayle (Údar), Lidia Oostvogels (Údar), Fernanda Tavares Da Silva (Údar), Ventzislav Vassilev (Údar), Carlota Vinals (Údar), Alain Brecx (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Taylor & Francis Group, 2018-07-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Introduction: GSK has developed a two-dose adjuvanted recombinant zoster vaccine (Shingrix, RZV) to protect people aged ≥50 years (50+) against herpes zoster (HZ) and its complications. RZV showed >90% efficacy against HZ, sustained over 4 years of follow-up, in all studied age groups. Areas cove...